Key result
Hydroquinidine prolongs QT by ~99 ms and prevents VF induction in short QT syndrome.
Why the study?
Short QT syndrome is a genetic disease linked to sudden death and arrhythmias, and effective pharmacological treatments to prolong the QT interval and prevent ventricular arrhythmias needed evaluation.
Do antiarrhythmic drugs prolong the QT interval and prevent ventricular arrhythmias in patients with short QT syndrome?
Comparison
Various antiarrhythmic drugs including flecainide, sotalol, ibutilide, and hydroquinidine
Authors
Loading...
May support antiarrhythmic use in short QT syndrome; leaves open need for larger confirmatory trials.
Do antiarrhythmic drugs prolong the QT interval and prevent ventricular arrhythmias in patients with short QT syndrome?
Hydroquinidine effectively prolongs the QT interval and prevents ventricular fibrillation inducibility in patients with short QT syndrome, offering a potential pharmacological therapy especially for young children.
Gaïta et al. (2004) studied Short QT syndrome (n=6). Antiarrhythmic drugs (flecainide, sotalol, ibutilide, and hydroquinidine) vs. Baseline was evaluated on QT interval prolongation and prevention of ventricular arrhythmias. Hydroquinidine administration prolonged the QT interval from 263 ± 12 ms to 362 ± 25 ms and prevented induction of ventricular fibrillation in patients with short QT syndrome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: